ArticleCell reports2022

BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis.

Vijaya Bharti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.